Clinical Trial Update: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of co-administering GSK Meningococcal Group B Vaccine with a 13-valent pneumococcal vaccine and routine infant vaccines …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Pneumococcal Disease

Drugs mentioned

• GSK Meningococcal Group B Vaccine
• Pneumococcal conjugate vaccine, 13-valent (Pneumococcal conjugate vaccine, 13-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2026-02-10